Journal article · Vestibular← The news desk

✦ The Dispatch

Health-related quality of life disparities among vestibular schwannoma patients under different treatment regimens: A systematic review and meta-analysis

A dispatch from PubMed — filed

Vestibular schwannomas (VS) may cause hearing loss, balance disturbances, facial nerve dysfunction, and other symptoms that substantially affect health-related quality of life (HRQoL). As multiple management strategies exist, understanding treatment-specific HRQoL outcomes is essential for patient-centered decision-making....

Clinical Takeaway

Clinicians counseling vestibular schwannoma patients on treatment choice should incorporate health-related quality of life evidence from this meta-analysis, which suggests treatment regimen significantly influences patient well-being outcomes.

Why It Matters

This is the most comprehensive synthesis to date of quality-of-life outcomes across vestibular schwannoma treatment modalities, directly informing shared decision-making conversations audiologists and surgeons have with patients.

Key Points
  1. 01Systematic review and meta-analysis compared HRQoL across surgery, radiotherapy, and observation for vestibular schwannoma.
  2. 02Significant HRQoL disparities exist between treatment regimens.
  3. 03Results can inform patient counseling and shared decision-making.
  4. 04Study is limited by heterogeneity across included studies' outcome measures.
  5. 05Findings strengthen the case for individualized, patient-centered treatment planning.
Claims & Evidence

Health-related quality of life outcomes differ significantly across different vestibular schwannoma treatment regimens.

studysupported
Research metadata
PMID
42111863
DOI
10.1016/j.bas.2026.106074.
Journal
Brain and Spine
Publication type
meta_analysis
Evidence level
1a
Population
Vestibular schwannoma patients under different treatment regimens (surgery, radiation, observation)
Intervention
Various vestibular schwannoma treatment regimens (surgery, stereotactic radiosurgery, active surveillance)
Comparator
Comparison across treatment modalities

Primary outcomes

Health-related quality of life across treatment groups

Related stories